Dextromethorphan Added on for Children With Chronic Irritability

Tri-Service General Hospital120 enrolled

Overview

Objectives: It is known that the etiology and mechanism of neuropsychiatric diseases may be related to nerve inflammation. It has been found that dextromethorphan (DM) is an active ingredient in cough-remedies, which can protect neurons in glial cell cultures in the rat brain from inflammatory substances. Although the mechanism of DM is still unknown, it may be related to the regulation of immune dysfunction. Therefore the purpose of this present study was to investigate the adjuvant treatment with DM in the children and adolescents with chronic irritability. Methods: This randomized double-blind clinical trial will evaluate 120 outpatients, aged between 7 and 17 years, with chronic irritability. The study subjects will be randomly assigned into one of the two groups: receiving routine medicine plus DM or routine medicine plus placebo for 8 weeks. Assessments comprising the parents' reported Mood Disorder Questionnaire (MDQ), Affective Reactivity Index (ARI), the Chinese version of the Child Behavior Checklist (CBCL-C) scale, the Swanson, Nolan and Pelham Questionnaire (SNAP-IV), the Sleep Disturbance Scale for Children (SDSC), Problematic smartphone use (PSU) and Checklist for Autism Spectrum Disorder-Chinese Version (CASD-C). Comparison will be done between groups at baseline and at 8 weeks before-and-after the treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

120

Conditions

Irritable Mood

Interventions

DextromethorphanDRUG

add on therapy

placeboOTHER

add on therapy

Eligibility

Sex: ALLMin age: 7 YearsMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients aged 7 to 17 who have irritability symptoms will be recruited. They will be screened for the irritability symptoms with ARI scale. Exclusion Criteria: * Patients who are not willing to participate in the study after detailed explanation. * Patients who could not follow the investigator's instructions. * Patients who have problems to express questions or emotional problems exactly. * Patients who have severe neurological or mental illness like epileptic disorder, history of stroke, schizophrenia, bipolar disorder, mental retardation or uncontrolled suicide risk. * Patients who have severe medical illness or surgical conditions like uncontrolled abnormal thyroid function, history of heart attack, uncontrolled hypertension. * Patients who are allergic to methylphenidate or dextromethorphan. * Patients with autoimmune disorders * Patients with asthma or severe infection disorder currently or in the previous two months to avoid the influence of the level of cytokines.

Locations (1)

Tri-Service General Hospital, National Defense Medical Center

Taipei, Taiwan

Outcomes

Primary Outcomes

Irritability severity

The investigators will measure if the severity improve after using regrow by the ARI scale.

Time frame: 8 weeks

Secondary Outcomes

ADHD severity

The investigators will measure if the severity improve after using regrow with regular drug by the SNAP-IV scale.

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.